Takeda Ventures

About

Portfolio · 2

Ramino-Bio

Oral drug for treating cardio-metabolic disease and rare MSUD

1 round Latest: 2018-09

Pi Therapeutics

Inhibitors for Cancer Treatment

1 round Latest: 2017-01

Investment activity

2 portfolio exits on record.

Q&A

What is Takeda Ventures' primary investment focus?

Takeda Ventures, the corporate investment arm of Takeda Pharmaceuticals, focuses on high-caliber therapeutic and platform-based opportunities globally, particularly in areas aligned with Takeda's R&D focuses, including Oncology, Gastroenterology, Neuroscience, and Rare Disease.

What are some of Takeda Ventures' notable exits?

Takeda Ventures has seen exits including ImmPACT Bio, which was acquired by Lyell Immunopharma in October 2024, and BiomX, which completed a reverse merger in November 2019.

Which investment stages does Takeda Ventures typically target?

Takeda Ventures invests in Seed, A Round, and B Round stages, with a focus on early-stage opportunities.

Can you name some of Takeda Ventures' portfolio companies?

Takeda Ventures' portfolio includes companies such as BiomX, focused on microbiome therapies, and ImmPACT Bio, which develops CAR-T cell therapies for cancer.

What is Takeda Ventures' geographic focus for investments?

Takeda Ventures focuses on therapeutic and platform-based opportunities around the world, without specific preferred geographies listed beyond a global scope.

When was Takeda Ventures founded?

Takeda Ventures was founded in 2001.

What is the most recent exit for Takeda Ventures?

The most recent exit for Takeda Ventures was ImmPACT Bio, which was acquired by Lyell Immunopharma in October 2024.

What is the sector concentration of Takeda Ventures' investments?

Takeda Ventures shows a strong concentration in the Health Tech & Life Sciences sector, with all 7 of its portfolio companies and 9 investment rounds falling within this sector.